Cargando…
P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621498/ http://dx.doi.org/10.1097/01.HS9.0000891004.90853.05 |
| _version_ | 1784821569961328640 |
|---|---|
| author | Moatti, Hannah Laroque, Marie-Céleste Renaud, Loïc. Ravdan, Odonchimeg Schmidt-Hieber, Charlotte Madelaine, Isabelle Di Blasi, Roberta Thieblemont, Catherine Brice, Pauline |
| author_facet | Moatti, Hannah Laroque, Marie-Céleste Renaud, Loïc. Ravdan, Odonchimeg Schmidt-Hieber, Charlotte Madelaine, Isabelle Di Blasi, Roberta Thieblemont, Catherine Brice, Pauline |
| author_sort | Moatti, Hannah |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9621498 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96214982022-11-01 P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma Moatti, Hannah Laroque, Marie-Céleste Renaud, Loïc. Ravdan, Odonchimeg Schmidt-Hieber, Charlotte Madelaine, Isabelle Di Blasi, Roberta Thieblemont, Catherine Brice, Pauline Hemasphere Relapsed/Refractory Lippincott Williams & Wilkins 2022-10-03 /pmc/articles/PMC9621498/ http://dx.doi.org/10.1097/01.HS9.0000891004.90853.05 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Relapsed/Refractory Moatti, Hannah Laroque, Marie-Céleste Renaud, Loïc. Ravdan, Odonchimeg Schmidt-Hieber, Charlotte Madelaine, Isabelle Di Blasi, Roberta Thieblemont, Catherine Brice, Pauline P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma |
| title | P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma |
| title_full | P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma |
| title_fullStr | P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma |
| title_full_unstemmed | P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma |
| title_short | P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma |
| title_sort | p109: one-day brentuximab-bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory hodgkin lymphoma |
| topic | Relapsed/Refractory |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621498/ http://dx.doi.org/10.1097/01.HS9.0000891004.90853.05 |
| work_keys_str_mv | AT moattihannah p109onedaybrentuximabbendamustine120mgm2every21daysisafeasibleandsafetreatmentforrelapsedrefractoryhodgkinlymphoma AT laroquemarieceleste p109onedaybrentuximabbendamustine120mgm2every21daysisafeasibleandsafetreatmentforrelapsedrefractoryhodgkinlymphoma AT renaudloic p109onedaybrentuximabbendamustine120mgm2every21daysisafeasibleandsafetreatmentforrelapsedrefractoryhodgkinlymphoma AT ravdanodonchimeg p109onedaybrentuximabbendamustine120mgm2every21daysisafeasibleandsafetreatmentforrelapsedrefractoryhodgkinlymphoma AT schmidthiebercharlotte p109onedaybrentuximabbendamustine120mgm2every21daysisafeasibleandsafetreatmentforrelapsedrefractoryhodgkinlymphoma AT madelaineisabelle p109onedaybrentuximabbendamustine120mgm2every21daysisafeasibleandsafetreatmentforrelapsedrefractoryhodgkinlymphoma AT diblasiroberta p109onedaybrentuximabbendamustine120mgm2every21daysisafeasibleandsafetreatmentforrelapsedrefractoryhodgkinlymphoma AT thieblemontcatherine p109onedaybrentuximabbendamustine120mgm2every21daysisafeasibleandsafetreatmentforrelapsedrefractoryhodgkinlymphoma AT bricepauline p109onedaybrentuximabbendamustine120mgm2every21daysisafeasibleandsafetreatmentforrelapsedrefractoryhodgkinlymphoma |